NICHOLAS J. VOGELZANG, M.D.                 

 

Click here for full CV

EXPERTISE: Urological Cancers

• Prostate Cancer
• Kidney Cancer
• Bladder Cancer

Chair and Medical Director Developmental Therapeutics and Member GU Committee US Oncology Research Comprehensive Cancer Centers, NV  

ACCOMPLISHMENTS, AWARDS AND HONORS:

• Schonfeld Memorial Lecture, Kidney Cancer Association 20th Anniversary meeting,Chicago, IL October 1, 2010
• Keynote Speaker, Japanese Society for Renal Cancer, 40th Anniversary, Tokyo, June 2010
• Visiting Professor; Juravinski Cancer Center in Hamilton, Ontario, Canada, November 27, 2008
• Annual award for distinguished volunteer at the Kidney Cancer Association’s Seventh International Kidney Cancer Symposium, Chicago, Illinois, September 2008
• “Best Doctors of Las Vegas,” by Las Vegas Woman Magazine, October/November 2008
• ASCO Statesman Award, ASCO Annual Meeting, Chicago, Illinois, June 2007
• Robert Hart Waldman, MD Lectureship of Medicine and the Visiting Professor, University of Nebraska Medical Center, Omaha, Nebraska, May 2007
• Health Care Hero in the category of Technology and Research by the Nevada Business Journal, The Four Season, Las Vegas, Nevada, July 31, 2007
• “52 Best Doctors in the City,” by Las Vegas Life Magazine, June 2005
• Citizen of Distinction, Foundation for an Independent Tomorrow, March 2005
• Souther Lecture Series – Providence Hospital, Portland Oregon, 2004
• “Chicago’s Top Doctors,” Chicago Magazine, January 2004
• Distinguished Trinity Christian College Alumni, 2003
• Best Doctors in America, 1994 to present
• Fred C. Buffett Professorship, University of Chicago, 1999 to 2003
• Castle Connolly Medical, Ltd., America’s Top Doctors, 2001; Chicago Metro Area, 2001
• American Cancer Society St. George National Award, 1999
• Listed in top 500 doctors in Chicago by Chicago Magazine, 1998, 2003, 2005
• Fellow - American College of Physicians, 1985
• Gould Foundation Scholar - University of Chicago, 1984
• American Cancer Society - Junior Faculty Fellowship, 1981 to 1984
• American Cancer Society - Institutional Research Grant, 1980, 1983
• American Cancer Society Clinical Fellow, University of Minnesota, 1978 to 1981
• Resident Award, Flick Family Fund, Rush Medical College, 1976
• Intern Award, John B. Drake Fund, Rush Medical College, 1975
• James Scholar, University of Illinois, 1971 to 1974
• Holstein Memorial Scholarship, Trinity Christian College, 1971
• National Marine Fisheries Service Research Grant, 1968 to 1970Argonne National Laboratory Student Research Award, 1968 to 1969
• Top Doctors 2011, Las Vegas Life, Spring 2011: Nicholas J Vogelzang, Research, Oncology – Comprehensive Cancer Centers of Nevada
• Desert Companion: 159 Best Physicians in Southern Nevada, as Chosen by their Peers: 

PROFESSIONAL EDUCATION & TRAINING:

Oncology Fellowship: Medical Oncology Fellow and Instructor, University of Minnesota, Minneapolis, MN

Residencies: Intern and Resident- Internal Medicine, Rush Presbyterian St. Luke's Medical Center, Chicago, IL. Chief Resident in Medicine and Instructor, Rush Presbyterian St. Luke's Medical Center, Chicago, IL. 

Medical School: M.D. University of Illinois Abraham Lincoln School of Medicine, Chicago, Illinois

Education: B.A. Trinity Christian College, Palos Heights, Illinois

PROFESIONAL/ ACADEMIC APPOINTMENTS:

• 2009 to present: Chair and Medical Director, Developmental Therapeutic Committee and member Genitourinary and Research Executive Committees, US Oncology Research, Houston, TX 
• 2009 to present: Medical Oncologist, Comprehensive Cancer Centers of Nevada, Las Vegas, NV
• 2004 to 2009: Director and Professor, Nevada Cancer Institute, Las Vegas, NV
• 2008 to 2009: Executive Vice President for Academic Affairs, Nevada Cancer Institute, Las Vegas, NV
• 2004 to Present: Head of the Genitourinary Oncology and Clinical Professor of Medicine, University of Nevada School of Medicine, Las Vegas/Reno, NV
• 2000 to 2003: Professor, Ben May Institute for Cancer Research, University of Chicago, Chicago, IL
• 1999 to 2003: Director, University of Chicago Cancer Research Center, Chicago, IL
• 1999 to 2003: The Fred C. Buffett Professor of Medicine and Chair in Genitourinary Oncology, University of Chicago, Chicago, IL
• 1993 to 2003: Professor of Medicine and Surgery (Urology), University of Chicago, Chicago, IL
• 1993 to 1999: Director of Genitourinary Oncology, University of Chicago, Chicago, IL
• 1982 to 2003:Member, University of Chicago Cancer Research Center, Chicago, IL
• 1987 to 1993: Associate Professor of Medicine and Surgery (Urology), University of Chicago, Chicago, IL
• 1982 to 1987: Assistant Professor of Medicine and Surgery (Urology), University of Chicago, Chicago, IL
• 1981 to 1982: Assistant Professor of Medicine, University of Minnesota, Minneapolis, MN
• 1978 to 1981: Medical Oncology Fellow and Instructor, University of Minnesota, Minneapolis, MN
• 1977 to 1978: Chief Resident in Medicine and Instructor, Rush Presbyterian St. Luke's Medical Center, Chicago, IL
• 1974 to 1977: Intern and Resident - Internal Medicine, Rush Presbyterian St. Luke's Medical Center, Chicago, IL

BOARD CERTIFICATIONS:

American Board of Internal Medicine: Internal Medicine

American Board of Internal Medicine: Medical Oncology

Diplomat of National Board of Medical Examiners

LOCAL AND NATIONAL COMMITTEES:

 

American Association for Cancer Research (AACR)

• Cancer Research Editorial Review Board, 1999 to 2002
• Illinois State Legislative Committee, 1992 to 2004
• Centennial Celebration Advisory Committee 2005
• Publication Committee, 2004 to 2006
• Kidney & Bladder Cancer Research session 2005
• Targeted Therapy for Renal Cancer Lecture, Anaheim Annual Meeting, 2005
• Science Policy and Legislative Affairs Committee, 2007 to 2009

American Cancer Society, Illinois Division (ACS)

• President, 1994 to 1996
• Immediate Past President, 1996 to 1998
• First Vice President, 1992 to 1994
• Second Vice President 1991 to 1992
• Board of Directors, 1986 to 1998
• Cancer Incidence and End Results Committee, 1986 to 1997
• Early Detection Committee, 1996 to 1998
• Field Service Committee, 1989 to 1991
• Institutional Grant Review Committee, 1982 to 1994
• Nominating Committee, 1990 to 1995
• Professional Education Committee, 1986 to 1996
• Public Relations Committee, 1986 to 1987

American Cancer Society, National (ACS)

• Cancer Editorial Advisory Board, 1988 to 2006
• Detection and Treatment Committee, 1997 to 1998
• Division Research Workgroup, 1997
• Host, ACS Excalibur Meeting, Chicago, 2001
• Medical Affairs Subcommittee on Questionable Methods of Cancer Management Committee, 1994
• National Board of Directors, 1994 to 1998
• Organizing Committee for National Conference on New Oncologic Agents, 1991; Prostate Cancer, 1997
• Prostate Cancer Committee, 1997 to 1999
• Psychosocial and Behavioral Research Advisory Committee, 1990 to 1991
• Research & Clinical Investigation Committee, 1994 to 1997
• Scientific Advisory Committee on Clinical Investigations-IV, 1992
• Scientific Advisory Committee, 1994 to 1997

American College of Physicians

• Presenter at Annual Sessions, 1987, 1991, 1992
• Reviewer for the first Medical Knowledge Self-Assessment Program in the Subspecialty of Oncology (MKSAP - Oncology), 1993
• Speaker Nevada Chapter ACP January 2009

American Foundation for Urologic Disease, Inc.

• Prostate Health Council, member, 1997 to 2003

American Society of Clinical Oncology (ASCO)

• Board of Directors, 1993 to 1996
• Cancer Communications Committee, 1998, 2009 to present.  Chair-elect 2011
• Cancer Education Committee, 2003 to 2009
• Chair, Bladder Cancer Poster Discussion, Annual Meeting, May, 1999
• Chair, Clinical Science Symposium, Annual Meeting, June, 2007
• Chairman, Patient Advocacy Committee, 1989 to 1991
• Discussant, GU Cancers Session, Annual meeting, 2000, 2001, 2004, 2005
• Discussant, Mesothelioma and Other Uncommon Thoracic Malignancies, Annual Meeting 2004, 2005, 2007
• Fall Conference, Chicago, IL “Bladder Cancer Tumor Board,” November, 1998
• JCO Editor Search Committee, 1996
• Joint ASCO/Blue Cross Blue Shield Technology Evaluation of Prostate Cancer Therapy, 1998
• Patient Advocacy Committee, Founding Chairperson, 1989 to 1992
• Program Committee, 1985 to 1986
• Program Committee, Sub-Chair of GU/Gyn Sessions, 1994 to 1995
• Program Committee 2003-2005, Sub-Chair of GU Committee 2003-04
• Best of ASCO lecture, San Francisco, California 2005
• Prostate Cancer Guideline Committee, 1996 to 2006
• Public Issues Committee, 1993 to 1996
• Public Relations Committee, 1987 to 1989
• Statesman Award, 2007
• GU Cancer Symposium Faculty Member, 2006, 2008

Association of American Cancer Institutes (AACI)

• Board of Directors, 2001 to 2004
• Nevada Cancer Institute Institutional Membership, 2007 to present
• University of Chicago Institutional Membership, 2000 to 2004

Cancer and Leukemia Group B (CALGB)

• CALGB Foundation Finance Committee, 1995 to 1999
• Chemotherapy Committee, 1985 to 1986
• Data Audit Committee, 1985 to 1990
• Executive Committee, 1990 to 1993
• GU Working Group Chair, 1988 to 1993
• Nominating Committee for New Chairman, 1988 to 1989
• Principal Investigator (Chicago), 1988 to 1999
• Prostate/GU Committee Chairman, 1993 to 1999, Member 1999 to 2003
• Respiratory Committee, 1986 to 1996
• Vice Chairman Data Audit Committee, 1988 to 1990
• Cancer Center External Advisory Boards, University of Minnesota 2002-03
• Winship Cancer Center Emory University, External Advisory Committee for Prostate Cancer, 1996 to 1997
• Hollings Cancer Center Medical University of South Carolina, 2007 to 2010
• Cancer Wellness Center, Skokie IL
• Advisory Board, 1987 to 2004

Center for Biomedical Continuing Education, Chairman:  Paul A. Bunn, Jr., M.D.

• Board Member, 2000 to 2006

Clinical Care Options Oncology

• Advisory Board Member 2006 - Present

Department of Defense

• Data Monitoring Board for the VA Cooperative Study #407, “Prostate Cancer 
• Intervention versus Observation trial (PIVOT),” 1995 to present
• Army Prostate Cancer Program, Senior Integration Panel, 1997 to 2005
• Chair of the Integration Panel, 2003-2004
• External DOD Advisor PCaP Consortium (J Mohler MD PhD P.I.), 2003 to 2008
• External DOD Advisor Clinical Trials Consortium (H Scher MD PI) 2003-2010

8th International Congress on Anti-Cancer Treatment

• Board of Advisors, 1997 to 1999
• Paris, France, February, 1998

Illinois Cancer Council

• Co-chairperson, Genito Urinary Committee, 1987 to 1992

International Association for the Study of Lung Cancer

• Member, 1982 to present
• Hilton Head, South Carolina, 1982
• Copenhagen, Denmark, 1985
• Tokyo, Japan, 1988
• Barcelona, Spain, 2005
• San Francisco, CA, 2009

Kidney Cancer Association

• Founder 1988-89
• President, 2004 to 2005
• Board of Trustees, 2002 to 2005
• Board Member, 1991 to 1996
• Chairman, Annual Meeting, Chicago, IL, 1998, 2003, 2004
• Medical Advisory Board, 1990 to 2000, 2010 to present
• National Volunteer Award, 2008
• Schonfeld Award 2010

LaGrange Memorial Hospital, La Grange, IL

• Active Consulting Staff, Department of Medicine, 1987 to 2002
• Medical Director, LaGrange Treatment Pavilion, 1987 to 1998

Mesothelioma Applied Research Foundation (MARF), Santa Barbara, CA

• Chairman of the Board, 2006 - 2010
• Board of Directors, 1999 to present
• Grant Review Board, 2003, 2004, 2006, 2007, 2008

National Cancer Institute (NCI) Committees

• Ad Hoc Committee for Selection of Phase I-III Contracts, 1984
• Ad Hoc Committee for Selection of Urology Research Groups, 1988
• Ad Hoc Committee for SPORE grants in Prostate Cancer, 1992
• Ad Hoc Committee for SPORE grants in GU/Lung Cancer, 2005
• Ad Hoc Review Committee for SPORE Grants in Lung and Lymphoma, 2008
• Ad Hoc Committee for the General Clinical Research Center, University of Pittsburgh, 5/1993
• Ad Hoc Advisor for Urology Research, 1988 (CCIRC Meeting -3/88)
• Co-Chair (with Peter Jones, Ph.D.):  Progress Review Group (PRG) Kidney and Bladder Cancer, 2001-2006
• Co-editor Kidney/Bladder Cancers Progress Review Group Report, August 2002
• External Review of laboratory of Molecular Biology (Ira Pastan, MD, P.I.), October 22 – 24, 2007
• External Review for Promotion of Raffitt Hassan, MD, Principal Investigator, Clinical Cancer Research, NCI
• Site Visitor, I. David Goldman, M.D., P.I., Albert Einstein Comprehensive Cancer Center, 2001
• Site Visitor, J. Bertino P0-1 application, Memorial Sloan Kettering Cancer Center, 12/1999
• Site Visitor, R. Comis, M.D., P.I., Eastern Cooperative Oncology Group, 2001
• Site Visitor, D. Sugarbaker, PO-1 Application, Dana Farber Harvard Cancer Center, 2004 – 2005
• Site Visitor, W. Dahut, M.D., P.I., NCI HIV/AIDS Malignancy and Prostate Program, April 20, 2008
• Special NIH Committee, "Therapeutic Clinical Trials of Malignancies, PAR-95-024," 11/14/1995
• Special NIH Review Committee, "Therapeutic Clinical Trials of Malignancies, PAR-95-023," 6/71995
• Study Section H (formerly CCRC) of the NIH/NCI, 1997 to 2002

Nevada Cancer Institute (NVCI) Committees

• Executive 2004-2009
• Strategic Performance and Excellence Council (SPEC) 2007- present
• Medical Oncology Fellowship 2005-present
• Promotions 2007-present
• Recruitment 2004-present
• Continuing Medical Education 2007-present

Pharmaceutical/Oncology Scientific Advisory Boards/ Speakers Bureau

• Abbott, 2000 to 2003
• Advanced Life Sciences, 2003
• Alfacell, 1996 to 2002
• Allos, 2006
• Ambit 2008-2010
• Amgen-Praecis, 1999 to 2000
• Amgen Denosumab DMSB 2004-2011
• Anagen, 2002
• Astrazeneca, 2004
• Augouron Pharmaceutical, 2000 to 2001
• Bayer, 2005, 2007, 2008
• Berlex, Quadramet Educational Advisory Board, 1999
• Berlex, Leukine Advisory Board, 2005
• Berlex Pharmaceuticals Prostate Cancer Advisory Board, 2006
• Corixa, P501 Vaccine, 2004
• Cougar/ J and J, Abiraterone, 2004 to 2010
• Dendreon, 1999, 2005, 2010
• Eli Lilly, 1997 to 2004
• EXIMIAS Pharmaceutical, 2004
• EMD/ Merck KGA 2002-2003
• Genentech, 1998 to 2002
• Genentech Renal Cell Carcinoma Community Advisory Board, 2009-2010
• Genta, 2001
• Glaxo-Wellcome/ GSK, 1997, 2006, 2009-2011
• Hana Biosciences, 2005
• HEM, 1991
• Immunex, 1995 to 1998
• Janssen, 1996
• Merck, 2003-2004
• NaPro, 1999
• Novartis, 1997, 2001, 2006 to 2011/ Global Speakers Bureau
• Onyvax, 2005
• Onyx, 2005 - present
• Ortho Biotech, 1992 to 1999
• OSI/Novantrone Prostate Cancer Advisory Board, 2002 to 2005
• Parke-Davis, 1997
• Pfizer, 2004 to 2011/ Global Speakers Bureau
• Pharmacia, 2003
• Praecis, 2003
• Rhone-Poulenc-Rorer/Aventis, 1998 to 2002
• Roche, 1987 to 1995
• Sanofi Aventis National prostate Cancer Advisory Board 2008-2011
• Schering Oncology Global Prostate Advisory Board 2006
• Searle, 1996 to 1998
• TAP, 1996 to 2002
• The Prostate Net, 2009
• Veridex 2008-2011
• Wilex 2003-2011
• Wyeth 2007-2010

Rush Medical School

• Admissions, 1977 to 1978
• Intern Selection, 1976 to 1977
• Senior Faculty Evaluation and Promotion, 1977 to 1978

Southwest Oncology Group (SWOG)

• Member 2006 -present
• Vice Chair GU Committee, 2007 to Present 
• GU Translational Medicine Intergroup Committee, 2007 to Present

University of Chicago Cancer Research Center (UCCRC)

• Director, 1999 to 2003
• Associate Director Clinical Sciences, 1998 to 1999
• Cancer Clinical Trials Review Committee, Vice-Chair, 1992 to 1994
• Member, Executive Committee, 1995 to 2003
• Program Leader, Prostate Cancer Program, 1995 to 1999
• Protocol and Data Management Office Faculty Advisory Board, 1997 to 1999

University of Chicago Institutional Committees

• Dean’s Ad Hoc Advisory Committee, 2003
• Argonne National Laboratory - Institutional Review Board, 1987 to 1990
• Chemotherapy Committee, 1982 to 1983
• Clinical Investigation Committee (IRB), 1983 to 1988
• Clinical Research Support Office, 2000 to 2002
• Continuing Medical Education Committee, 1989 to 1994
• Executive Committee, 1997 to 1999
• Fellowship Selection Committee, Hematology/Oncology Section, 1983 to 2002
• Medical Legal Committee, 1993 to 1999
• Physicians’ Fund Raising Working Group, 1999 to 2001
• Radioisotope Committee, 1986 to 1988
• Review Committee for Dermato-Pathology, 2002
• Search Committees: Chair of the Department of OB/GYN, 2000
• Ludwig Chair of the Ben May Institute for Cancer Research, 2000 to 2002
• Knapp Center Director, 1998
• Working Group on Referring Physician Strategies, 1987 to 1988

University of Minnesota Medical School

• Admissions, 1979 to 1980

US Too

• Medical Advisory Board, 2000 to present
• Scientific Advisory Board, 2000 to present

 

RESEARCH:

1.   Algeta USA (WIRB# 1113976) 10/18/2010
P.I.: Nicholas J. Vogelzang, M.D.
A double-blind, randomised, multipled dose, Phase III, multicentre study of Alpharadin in the treatment of patients with symptomatic hormone refractory prostate cancer with skeletal metastases.
    
2.   Cougar Biotechnology COU-AA-301 03/2010
    P.I.:  Nicholas J. Vogelzang, M.D.
    A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy

3   Cougar Biotechnology COU-AA-302 04/2009
P.I.: Nicholas J. Vogelzang
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prostate Cancer

4.   Dendreon (IND# BB-IND 6933) 06/29/2010
    A Registry of Sipuleucel-T Therapy in men with advanced prostate Cancer

5.   Tokai (IND# 104,183) TOK – 001, TOK-200-05 09/2009
Phase 1/2., Open label, dose escalation, selected dose comparison trail of TOK-001 for the Treatment of Chemotherapy naïve castration resistant Prostate Cancer